Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.10%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.71%XMRUSDT+7.26%DOGEUSD+72.43%LINKUSD+1.21%XLMUSD+1.89%BCHUSDT+2.52%LTCUSD+64.72%UNIUSD+5.22%TONUSD+74.91%SUIUSD-0.57%HBARUSDT+0.53%TAOUSDT+2.81%AAVEUSD-0.31%ONDOUSDT-0.55%DOTUSDT-1.75%ICPUSDT-5.75%WLDUSDT-0.52%ARBUSDT-1.10%ATOMUSDT-3.84%INJUSDT-4.42%STXUSDT+2.91%PYTHUSDT+0.50%TIAUSDT-1.31%FETUSDT-3.25%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.57%OPUSDT+0.63%IOTAUSDT-1.68%POLUSDT-0.06%WIFUSDT-2.78%AXSUSDT+0.75%EOSUSDT+0.93%IMXUSDT-3.33%FARTCOINUSDT-0.21%GALAUSDT-1.39%DYDXUSDT-3.53%ORDIUSDT-0.23%NOTUSDT-1.52%RONINUSDT+0.62%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.10%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.71%XMRUSDT+7.26%DOGEUSD+72.43%LINKUSD+1.21%XLMUSD+1.89%BCHUSDT+2.52%LTCUSD+64.72%UNIUSD+5.22%TONUSD+74.91%SUIUSD-0.57%HBARUSDT+0.53%TAOUSDT+2.81%AAVEUSD-0.31%ONDOUSDT-0.55%DOTUSDT-1.75%ICPUSDT-5.75%WLDUSDT-0.52%ARBUSDT-1.10%ATOMUSDT-3.84%INJUSDT-4.42%STXUSDT+2.91%PYTHUSDT+0.50%TIAUSDT-1.31%FETUSDT-3.25%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.57%OPUSDT+0.63%IOTAUSDT-1.68%POLUSDT-0.06%WIFUSDT-2.78%AXSUSDT+0.75%EOSUSDT+0.93%IMXUSDT-3.33%FARTCOINUSDT-0.21%GALAUSDT-1.39%DYDXUSDT-3.53%ORDIUSDT-0.23%NOTUSDT-1.52%RONINUSDT+0.62%

Danaher’s Cepheid wins FDA test clearance

NEWS

November 4, 2026 at 12:09 UTC

3 min read
Unbranded PCR diagnostic analyzer in a clinical lab, illustrating FDA-cleared hemorrhagic fever test for DHR

Key Points

  • 01Danaher (DHR) unit Cepheid secured FDA clearance for the Xpert Hemorrhagic Fever Panel
  • 02The multiplex PCR test detects several hemorrhagic fever viruses, including Ebola
  • 03The assay delivers results from a single sample in about 61 minutes
  • 04The FDA nod is seen as significant for Danaher (DHR)’s diagnostics portfolio

FDA clears Danaher’s Xpert Hemorrhagic Fever Panel

Danaher’s diagnostics subsidiary Cepheid has obtained U.S. FDA clearance for its Xpert Hemorrhagic Fever Panel, a molecular test designed to detect multiple hemorrhagic fever viruses from a single patient sample. The authorization is a notable regulatory milestone for Danaher’s diagnostics franchise and could influence the bullish investment case for the company.

The Xpert Hemorrhagic Fever Panel is a multiplex polymerase chain reaction (PCR) assay that identifies several hemorrhagic fever viruses, including Ebola, using just one specimen. The test is designed to provide results in approximately 61 minutes, offering clinicians a rapid diagnostic option when evaluating suspected cases of hemorrhagic fevers.

Cepheid announced the FDA decision on a Tuesday, underscoring that the panel is built to address multiple pathogens within a single workflow. By combining multi-pathogen detection with a relatively fast turnaround time, the product is positioned within Danaher’s broader portfolio of molecular diagnostic solutions.

Test capabilities and clinical use context

The Xpert Hemorrhagic Fever Panel is categorized as a multiplex PCR test, meaning it can simultaneously detect more than one viral target in a single run. In this case, the assay is configured to identify several hemorrhagic fever viruses from one patient sample, which can help streamline testing in settings where multiple agents may be in circulation.

Hemorrhagic fever viruses, such as Ebola, have been associated with severe outbreaks, and rapid identification of the causative virus is central to patient management and infection control. The roughly 61-minute time to result is intended to support quicker decision-making compared with traditional approaches that may require longer processing times or multiple separate tests.

By integrating multiple targets into a single cartridge-based test, the panel may reduce the need for sequential testing when clinicians face non-specific symptoms that could be caused by different hemorrhagic fever viruses. This consolidated workflow aligns with Cepheid’s broader emphasis on point-of-care and near-patient molecular testing.

Implications for Danaher and Cepheid

The FDA clearance enhances Danaher’s portfolio in high-consequence infectious disease diagnostics through its Cepheid business. Investors have highlighted the development as a factor that could shape the bullish narrative around Danaher, particularly within its diagnostics and life sciences exposure.

Cepheid, as a subsidiary of Danaher, expands the parent company’s capabilities in PCR-based diagnostics with the addition of this hemorrhagic fever panel. The new approval adds to the company’s suite of tests targeting critical infectious diseases and reflects ongoing investment in molecular testing platforms.

While financial metrics tied to the product were not disclosed, the regulatory milestone underscores Danaher’s continued involvement in advanced diagnostic technologies. The clearance of the Xpert Hemorrhagic Fever Panel reinforces the company’s role in supporting rapid detection of serious viral threats within clinical settings.

Key Takeaways

  • 01FDA clearance of Cepheid’s hemorrhagic fever panel strengthens Danaher (DHR)’s position in molecular diagnostics for high-impact infectious diseases.
  • 02Rapid, multiplex detection of several hemorrhagic fever viruses from a single sample highlights an efficiency-focused design for clinical settings.
  • 03The regulatory milestone is viewed as a meaningful input into the positive investment narrative surrounding Danaher’s diagnostics franchise.

Danaher’s Cepheid wins FDA test clearance | Trading Dashboard